Over 70% of T-ALL patients carry gain-of-function mutations in transmembrane receptor NOTCH1, inducing ligand-independent activation or delayed degradation of intracellular NOTCH1. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.